Keros Therapeutics, Inc. announced on July 17, 2025, that the first patient has been dosed in the Phase 3 RENEW clinical trial of elritercept. This trial is evaluating elritercept in adults with transfusion-dependent anemia associated with very low, low, or intermediate risk myelodysplastic syndromes (MDS).
The initiation of patient dosing in the RENEW trial represents a significant advancement for elritercept, a key product candidate in Keros' pipeline. This milestone also triggered a $10 million payment to Keros under its global license agreement with Takeda Pharmaceutical Company Limited.
Under the terms of the agreement, which became effective on January 16, 2025, Keros previously received a $200 million upfront payment and is eligible for potential development, commercial, and sales milestones exceeding $1.1 billion. The Phase 3 RENEW trial's primary objective is to evaluate elritercept's efficacy in reducing red blood cell transfusions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.